Sign in
CompletedNo phase

Clareon PanOptix Pro vs. Clareon PanOptix - Study A

Key facts

Who runs it
Alcon Research
Where
Bloomfield Hills, Cincinnati, Houston, Kansas City, Mt. Pleasant, Nashville, Salt Lake City, and Torrance, United StatesSee the 8 sites
Trial code
Status
Completed
People taking part
87 people enrolled
Started
18 Jun 2024
Ended
30 Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CPO Pro IOL
  • CPO IOL
  • Cataract surgery
Record updated
12 December 2025

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Understand and sign an ethics committee-approved informed consent form
  • Willing and able to attend all scheduled study visits as required by the protocol
  • Planned cataract surgery (both eyes)
  • Preoperative corneal astigmatism less that 1.00 diopter in each eye
  • Other protocol-defined inclusion criteria may apply

Who cannot take part

  • Ocular conditions as specified in the protocol
  • Women of childbearing potential if currently pregnant, intend to become pregnant during the study, or are breastfeeding
  • Subjects who desire monovision correction
  • Other protocol-defined exclusion criteria may apply

Where in United States

  • Grosinger, Spigelman & Grey Eye Surgeons, P.C.Bloomfield Hills, United States
  • Cincinnati Eye InstituteCincinnati, United States
  • Houston Eye AssociatesHouston, United States
  • Moyes Eye CenterKansas City, United States
  • Carolina Eyecare Physicians LLCMt. Pleasant, United States
  • Vision for LifeNashville, United States
  • The Eye Institute of UtahSalt Lake City, United States
  • Wolstan & Goldberg Eye AssociatesTorrance, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.

The 2 groups in the trial

  • CPO Pro IOLTreatment being tested

    CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

    Treatment: CPO Pro IOL, CPO IOL, and Cataract surgery

  • CPO IOLExisting treatment, for comparison

    CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.

    Treatment: CPO Pro IOL, CPO IOL, and Cataract surgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Contralateral Study of Clareon PanOptix Pro vs. Clareon PanOptix
Record updated
12 December 2025